PGI-7043

PGI-7043 is a serotonin 5-HT 1B and 5-HT 1D receptor agonist.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 3 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

PGI-7043 is a serotonin 5-HT 1B and 5-HT 1D receptor agonist. It is a potent and highly centrally penetrant full agonist of the serotonin 5-HT 1B and 5-HT 1D receptors ( = 1.3 nM and 0.5 nM, respectively). The drug produces antidepressant-like, antiaggressive, and prosocial effects in rodents without producing sedation.

In contrast, zolmitriptan was only weakly effective at a 100-fold higher dose in terms of antidepressant-like effects. This may be related to triptans like zolmitriptan having limited blood–brain barrier permeability and hence being peripherally selective. Moreover, while olanzapine also produced antiaggressive effects, it produced sedation and reduced social interaction as well.

PGI-7043 suppressed rapid eye movement (REM) sleep as measured with electroencephalography (EEG) in rodents, which could serve as a novel translational biomarker for clinical studies. Serotonin 5-HT 1B and 5-HT 1D receptor occupancy were confirmed in rodents at doses producing behavioral and EEG effects. The drug is described as having excellent drug-like properties.

PGI-7043 was first described in the scientific literature in December 2024. It was discovered by PsychoGenics using their SmartCube drug discovery platform following screening of approximately 300 compounds.…

PGI-7043 is a serotonin 5-HT 1B and 5-HT 1D receptor agonist. It is a potent and highly centrally penetrant full agonist of the serotonin 5-HT 1B and 5-HT 1D receptors ( = 1.3 nM and 0.5 nM, respectively). The drug produces antidepressant-like, antiaggressive, and prosocial effects in rodents without producing sedation.

In contrast, zolmitriptan was only weakly effective at a 100-fold higher dose in terms of antidepressant-like effects. This may be related to triptans like zolmitriptan having limited blood–brain barrier permeability and hence being peripherally selective. Moreover, while olanzapine also produced antiaggressive effects, it produced sedation and reduced social interaction as well.

PGI-7043 suppressed rapid eye movement (REM) sleep as measured with electroencephalography (EEG) in rodents, which could serve as a novel translational biomarker for clinical studies. Serotonin 5-HT 1B and 5-HT 1D receptor occupancy were confirmed in rodents at doses producing behavioral and EEG effects. The drug is described as having excellent drug-like properties.

PGI-7043 was first described in the scientific literature in December 2024. It was discovered by PsychoGenics using their SmartCube drug discovery platform following screening of approximately 300 compounds.

The drug might have therapeutic applications in the treatment of conditions like agitation in Alzheimer's disease, bipolar disorder, and schizophrenia as well as treatment of reduced social behavior in autism spectrum disorders. Its chemical structure does not yet appear to have been disclosed.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1334426577 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.